AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11282268 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pefloxacin (800 mg)
Number of subjects: 50
Study 9080935 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of cigarette package warning labels
Number of subjects: 1747
Study 9080935 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of warning labels on cigarette advertisements
Number of subjects: 1747
Study 8292723 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of vitamin K1 orally in addition to the usual warfarin dose (group B)
Number of subjects: 23
Study 8292723 — intervention group
Group type: COMPARATOR
Intervention: Discontinued warfarin for one day (group A)
Number of subjects: 23
Study 8292723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups continued with their usual dose of warfarin after day 1
Number of subjects: 23
Study 3100910 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary weight loss (n = 12)
Number of subjects: 26
Study 3100910 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise (n = 14)
Number of subjects: 26
Study 30582156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment, titrated from 2.5 to 20 mg/kg/d, with a maximum of 30 mg/kg/d based on response and tolerance.
Number of subjects: 264
Study 30582156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) treatment
Number of subjects: 264
Study 28981901 — intervention group
Group type: EXPERIMENTAL
Intervention: Errorless learning plus ongoing supported employment
Number of subjects: 162
Study 28981901 — intervention group
Group type: COMPARATOR
Intervention: Ongoing supported employment alone
Number of subjects: 162
Study 26933876 — intervention group
Group type: EXPERIMENTAL
Intervention: Phendimetrazine (35, 70, and 105mg)
Number of subjects: 9
Study 26933876 — intervention group
Group type: EXPERIMENTAL
Intervention: d-Amphetamine (10, 20, and 30mg)
Number of subjects: 9
Study 26933876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 24393516 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality development process
Number of subjects: 104
Study 24393516 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 104
Study 22446297 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 group 2 (25mg twice daily)
Number of subjects: 86
Study 22446297 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX group (10 mg/week for the first 4 weeks and 15 mg/week for the subsequent 20 weeks)
Number of subjects: 86
Study 22446297 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 (50 μg/ml)
Number of subjects: 86
Study 22446297 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 (5 μg/ml or more)
Number of subjects: 86
Study 22446297 — intervention group
Group type: EXPERIMENTAL
Intervention: T-614 treatment
Number of subjects: 86
Study 20173715 — intervention group
Group type: EXPERIMENTAL
Intervention: Short prophylactic therapy (2 grams of amoxicillin 1 hour before the procedure and 1 gram 6 hours after surgery)
Number of subjects: 160
Study 20173715 — intervention group
Group type: COMPARATOR
Intervention: Long postoperative regimen (1 gram of amoxicillin 6 hours after surgery followed by 1 gram every 8 hours for 4 days)
Number of subjects: 160
Study 17610900 — intervention group
Group type: EXPERIMENTAL
Intervention: Microendoscopic discectomy (MED)
Number of subjects: 23
Study 17610900 — intervention group
Group type: COMPARATOR
Intervention: Open discectomy (OD)
Number of subjects: 23
Study 16230754 — intervention group
Group type: EXPERIMENTAL
Intervention: Family involvement in care
Number of subjects: 400
Study 16230754 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff encouragement
Number of subjects: 400
Study 14664688 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed model approach for evaluating therapy studies
Number of subjects: 0
Study 14664688 — intervention group
Group type: COMPARATOR
Intervention: Proposed approach by Crits-Christoph et al
Number of subjects: 0
Study 10641419 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive periodontal treatment with emphasis on oral hygiene
Number of subjects: 34
Study 10641419 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine administration
Number of subjects: 34
Study 8889288 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 5 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Number of subjects: 13
Study 8889288 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine 15 mg p.o. b.i.d. + molindone 150 mg p.o. q.d.
Number of subjects: 13
Study 8889288 — intervention group
Group type: COMPARATOR
Intervention: Placebo + molindone 150 mg p.o. q.d.
Number of subjects: 13
Study 1724390 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF) 0.5 micrograms/kg injected subcutaneously for 6 consecutive days
Number of subjects: 0
Study 1724390 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human granulocyte colony-stimulating factor (rhG-CSF)
Number of subjects: 0
Study 6362553 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin‐clavulanic acid (A‐C) for 10 days
Number of subjects: 66
Study 6362553 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor for 10 days
Number of subjects: 66
Study 3543835 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexcelite
Number of subjects: 82
Study 3543835 — intervention group
Group type: COMPARATOR
Intervention: Plaster of Paris
Number of subjects: 82
Study 29765151 — intervention group
Group type: EXPERIMENTAL
Intervention: Apatorsen plus docetaxel (A/D)
Number of subjects: 200
Study 29765151 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel alone
Number of subjects: 200
Study 29083220 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 454
Study 29083220 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral relapse prevention
Number of subjects: 454
Study 29083220 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 454
Study 24714660 — intervention group
Group type: COMPARATOR
Intervention: 600 IU/day of vitamin D (control group, n = 31)
Number of subjects: 91
Study 24714660 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,200 IU/day of vitamin D (n = 31)
Number of subjects: 91
Study 24714660 — intervention group
Group type: EXPERIMENTAL
Intervention: 2,000 IU/day of vitamin D (n = 32)
Number of subjects: 91
Study 23972694 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR administered in the morning (1-4 mg/d)
Number of subjects: 333
Study 23972694 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR administered in the evening (1-4 mg/d)
Number of subjects: 333
Study 23972694 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered twice daily
Number of subjects: 333
Study 23972694 — intervention group
Group type: EXPERIMENTAL
Intervention: GXR all-active (morning and evening)
Number of subjects: 333
Study 20339952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac auscultation curriculum (computer tutorial and cardiac patient simulator)
Number of subjects: 108
Study 17976225 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep anesthesia with desflurane (25% concentration)
Number of subjects: 20
Study 17976225 — intervention group
Group type: COMPARATOR
Intervention: Light anesthesia with desflurane (50% concentration)
Number of subjects: 20
Study 17976225 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (deep and light)
Number of subjects: 20
Study 16761155 — intervention group
Group type: EXPERIMENTAL
Intervention: Day hospital nurses handling antineoplastic drugs
Number of subjects: 30
Study 16761155 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 30
Study 16761155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ward nurses and pharmacy technicians
Number of subjects: 30
Study 16761155 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocytes from exposed groups
Number of subjects: 30
Study 12409635 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (n = 1,422)
Number of subjects: 2232
Study 12409635 — intervention group
Group type: COMPARATOR
Intervention: Diet therapy (n = 810)
Number of subjects: 2232
Study 9836156 — intervention group
Group type: EXPERIMENTAL
Intervention: 70% isopropyl alcohol cleansing at each diaper change
Number of subjects: 1811
Study 9836156 — intervention group
Group type: COMPARATOR
Intervention: Natural drying of the umbilical site without special treatment
Number of subjects: 1811
Study 7915921 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol
Number of subjects: 16
Study 7915921 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 micrograms formoterol
Number of subjects: 16
Study 7915921 — intervention group
Group type: COMPARATOR
Intervention: 200 micrograms salbutamol
Number of subjects: 16
Study 7915921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2910758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (400 mg twice daily for 1 week)
Number of subjects: 6
Study 2910758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (50 mg/kg body wt) in rats
Number of subjects: 6
Study 2910758 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (in vitro)
Number of subjects: 6
Study 2910758 — intervention group
Group type: COMPARATOR
Intervention: Control (no cimetidine)
Number of subjects: 6
Study 1275144 — intervention group
Group type: EXPERIMENTAL
Intervention: Wound drainage
Number of subjects: 92
Study 1275144 — intervention group
Group type: COMPARATOR
Intervention: No wound drainage (Control)
Number of subjects: 92
Study 31641887 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (50 mg/day)
Number of subjects: 30
Study 31641887 — intervention group
Group type: COMPARATOR
Intervention: Voglibose (0.6 mg/day)
Number of subjects: 30
Study 30360748 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Levofloxacin (TAVANEX), 750 mg, once daily for five days
Number of subjects: 150
Study 30360748 — intervention group
Group type: COMPARATOR
Intervention: Parenteral Ceftriaxone 1gr BD plus oral Azithromycin (250 mg, once daily) for seven to ten days
Number of subjects: 150
Study 27759629 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles (CNs)
Number of subjects: 82
Study 27759629 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 24807156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 7.5 mg/kg
Number of subjects: 303
Study 24807156 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg
Number of subjects: 303
Study 24807156 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab (both dosages)
Number of subjects: 303
Study 22455751 — intervention group
Group type: EXPERIMENTAL
Intervention: Premier HQID hospitals
Number of subjects: 3363
Study 22455751 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (public reporting only)
Number of subjects: 3363
Study 22455751 — intervention group
Group type: EXPERIMENTAL
Intervention: Premier HQID hospitals (poor performers at baseline)
Number of subjects: 3363
Study 22455751 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals (poor performers at baseline)
Number of subjects: 3363
Study 20197510 — intervention group
Group type: EXPERIMENTAL
Intervention: High tobacco smoke exposure (high cotinine group)
Number of subjects: 494
Study 20197510 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate tobacco smoke exposure (intermediate cotinine group)
Number of subjects: 494
Study 20197510 — intervention group
Group type: COMPARATOR
Intervention: Low tobacco smoke exposure (low cotinine group)
Number of subjects: 494
Study 18824931 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg x kg(‐1))
Number of subjects: 15
Study 18824931 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (10 mg x kg(‐1))
Number of subjects: 15
Study 18824931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 15597182 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional stimulus-response set in Experiment 1
Number of subjects: 0
Study 15597182 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-dimensional Simon tasks with two contralateral effectors in Experiments 2 and 3
Number of subjects: 0
Study 15597182 — intervention group
Group type: EXPERIMENTAL
Intervention: Horizontal coding in Experiment 4
Number of subjects: 0
Study 15597182 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical coding in Experiment 4
Number of subjects: 0
Study 14707397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA) 750 mg/day for 6 months
Number of subjects: 20
Study 14707397 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 months
Number of subjects: 20
Study 14707397 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (UDCA)
Number of subjects: 20
Study 14707397 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 10409867 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuit diving apparatuses (breathing gas compositions: 24 m: 60% O2/40% N2, 42 m: 40% O2/60% N2, 54 m: 32.5% O2/67.5% N2)
Number of subjects: 15
Study 10409867 — intervention group
Group type: COMPARATOR
Intervention: Compressed air diving apparatuses (breathing gas: 21% O2/78% N2)
Number of subjects: 15
Study 7676787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with 1.0 mg alfentanil
Number of subjects: 400
Study 7676787 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 400
Study 7676787 — intervention group
Group type: COMPARATOR
Intervention: Thiopentone
Number of subjects: 400
Study 7676787 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil
Number of subjects: 400
Study 7676787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 400
Study 2305332 — intervention group
Group type: EXPERIMENTAL
Intervention: Pivampicillin (700 mg twice daily for 9 days)
Number of subjects: 80
Study 2305332 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline (200 mg on the first day, then 100 mg daily plus one placebo tablet for 9 days)
Number of subjects: 80
Study 437309 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllocontin Continus tablets
Number of subjects: 37
Study 31919540 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mA tDCS
Number of subjects: 16
Study 31919540 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mA tDCS
Number of subjects: 16
Study 31919540 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 16
Study 31864818 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-construct PEEK anchor
Number of subjects: 69
Study 31864818 — intervention group
Group type: COMPARATOR
Intervention: Non-vented biocomposite anchor
Number of subjects: 69
Study 31864818 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Open-construct PEEK anchor and Non-vented biocomposite anchor)
Number of subjects: 69
Study 30586441 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth kit use
Number of subjects: 3317
Study 27146504 — intervention group
Group type: EXPERIMENTAL
Intervention: Lichtenstein repair
Number of subjects: 67
Study 27146504 — intervention group
Group type: COMPARATOR
Intervention: Darning repair
Number of subjects: 67
Study 24457604 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 5 mg
Number of subjects: 237
Study 24457604 — intervention group
Group type: EXPERIMENTAL
Intervention: UPA 10 mg
Number of subjects: 237
Study 24457604 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 237
Study 22980429 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acetic acid gel
Number of subjects: 48
Study 22980429 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 48
Study 20195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum IL-6 above the 90th percentile
Number of subjects: 475
Study 20195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum CRP above the 90th percentile
Number of subjects: 475
Study 20195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum IL-6 and CRP above the 90th percentile
Number of subjects: 475
Study 20195952 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum MMP-9
Number of subjects: 475
Study 17263884 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-2 therapy
Number of subjects: 14
Study 17263884 — intervention group
Group type: COMPARATOR
Intervention: No IL-2 therapy (Control)
Number of subjects: 14
Study 17263884 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CD8(+) T cell apoptosis
Number of subjects: 14
Study 16178407 — intervention group
Group type: EXPERIMENTAL
Intervention: Canalith repositioning maneuver with postmaneuver activity restrictions (restricted group)
Number of subjects: 42
Study 16178407 — intervention group
Group type: COMPARATOR
Intervention: Canalith repositioning maneuver without postmaneuver activity restrictions (nonrestricted group)
Number of subjects: 42
Study 16178407 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmaneuver restrictions
Number of subjects: 42
Study 12109340 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 10540675 — intervention group
Group type: EXPERIMENTAL
Intervention: Double paper wipe cleaning method for fit patients
Number of subjects: 0
Study 10540675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single paper wipe followed by alcohol wipe for patients at risk of infection
Number of subjects: 0
Study 10540675 — intervention group
Group type: EXPERIMENTAL
Intervention: Single paper wipe followed by alcohol wipe for patients with a potential source of infection
Number of subjects: 0
Study 8983287 — intervention group
Group type: EXPERIMENTAL
Intervention: SCM test using the Cellscan system
Number of subjects: 153
Study 1752914 — intervention group
Group type: EXPERIMENTAL
Intervention: temazepam Gelthix (TG)
Number of subjects: 24
Study 1752914 — intervention group
Group type: COMPARATOR
Intervention: liquid-filled soft gelatin capsules (TL)
Number of subjects: 24
Study 6810204 — intervention group
Group type: EXPERIMENTAL
Intervention: Sinemet (levodopa plus carbidopa)
Number of subjects: 0
Study 6810204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 0
Study 6810204 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 6810204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbidopa
Number of subjects: 0
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based diets with 6.30% fat
Number of subjects: 16
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based diets with 13.9% fat
Number of subjects: 16
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based diets with 22.0% fat
Number of subjects: 16
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based diets with 34.0% fat
Number of subjects: 16
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil
Number of subjects: 16
Study 30463437 — intervention group
Group type: EXPERIMENTAL
Intervention: Soybean oil-based diets
Number of subjects: 16
Study 28281736 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping
Number of subjects: 50
Study 28281736 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet function testing (PFT)
Number of subjects: 50
Study 28281736 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 50
Study 27119309 — intervention group
Group type: EXPERIMENTAL
Intervention: Left axillary implantation of ILR
Number of subjects: 63
Study 27119309 — intervention group
Group type: COMPARATOR
Intervention: Traditional left chest area implantation of ILR
Number of subjects: 63
Study 24612007 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS health messages in local languages sent to the intervention group over 6 weeks
Number of subjects: 53
Study 24612007 — intervention group
Group type: COMPARATOR
Intervention: Control group (no MMS health messages)
Number of subjects: 53
Study 24612007 — intervention group
Group type: EXPERIMENTAL
Intervention: MMS health messages in local languages
Number of subjects: 53
Study 22390878 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic print‐delivered intervention
Number of subjects: 0
Study 22390878 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic Web‐based intervention
Number of subjects: 0
Study 22390878 — intervention group
Group type: EXPERIMENTAL
Intervention: Print‐delivered intervention with an additional environmental component
Number of subjects: 0
Study 22390878 — intervention group
Group type: EXPERIMENTAL
Intervention: Web‐based version with an additional environmental component
Number of subjects: 0
Study 22390878 — intervention group
Group type: EXPERIMENTAL
Intervention: Pretest results
Number of subjects: 0
Study 22390878 — intervention group
Group type: COMPARATOR
Intervention: Print‐delivered and Web‐based interventions
Number of subjects: 0
Study 20849613 — intervention group
Group type: EXPERIMENTAL
Intervention: Community mobilisation intervention through women's groups
Number of subjects: 48000
Study 20849613 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-led infant feeding and care support intervention
Number of subjects: 48000
Study 20849613 — intervention group
Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 48000
Study 17437498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco 703 (D703)
Number of subjects: 60
Study 17437498 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideco 903 (D903)
Number of subjects: 60
Study 17437498 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrox
Number of subjects: 60
Study 17437498 — intervention group
Group type: EXPERIMENTAL
Intervention: All oxygenators
Number of subjects: 60
Study 15812103 — intervention group
Group type: EXPERIMENTAL
Intervention: Community pharmacy-based coaching program including a take-home videotape
Number of subjects: 147
Study 15812103 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 147
Study 15812103 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 147
Study 11916761 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg FeSO4 twice daily for 6 weeks
Number of subjects: 41
Study 11916761 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily for 6 weeks
Number of subjects: 41
Study 9864077 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium (serum drug level 0.6+/‐0.1 mmol/L)
Number of subjects: 171